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Abstract
Background: Although over a hundred million dollars have been invested in offering free quadrivalent human
papillomavirus (HPV) vaccination to young girls in Ontario, there continues to be very little information about its
usage. In order to successfully guide future HPV vaccine programming, it is important to monitor HPV vaccine use
and determine factors associated with use in this population.
Methods: Linking administrative health and immunization databases, we conducted a population-based,
retrospective cohort study of girls eligible for Ontario’s Grade 8 HPV vaccination program in Kingston, Frontenac,
Lennox, and Addington. We determined the proportion of girls who initiated (at least one dose) and completed
(all three doses) the vaccination series overall and according to socio-demographics, vaccination history, health
services utilization, medical history, and program year. Multivariable logistic regression was used to estimate the
strength of association between individual factors and initiation and completion, adjusted for all other factors.
Results: We identified a cohort of 2519 girls, 56.6% of whom received at least one dose of the HPV vaccine. Among
vaccinated girls, 85.3% received all three doses. Vaccination history was the strongest predictor of initiation in that
girls who received the measles-mumps-rubella, meningococcal C, and hepatitis B vaccines were considerably more
likely to also receive the HPV vaccine (odds ratio 4.89; 95% confidence interval 4.04-5.92). Nevertheless, HPV vaccine
uptake was more than 20% lower than that of these other vaccines. In addition, while series initiation was not
influenced by income, series completion was. In particular, girls of low income were the least likely to receive all
three indicated doses of the HPV vaccine (odds ratio 0.45; 95% confidence interval 0.28-0.72).
Conclusions: The current low level of HPV vaccine acceptance in Kingston, Frontenac, Lennox, and Addington will
likely have important implications in terms of the health benefits and cost-effectiveness of its publicly funded
program. We identified important factors associated with series initiation and completion that should be
considered in efforts to improve HPV vaccine use in this population.
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Background
In July 2006, Health Canada approved Gardasil
®,a
quadrivalent human papillomavirus (HPV) vaccine
designed to protect against strains of HPV that cause
70% of cervical cancers [1] and 90% of genital warts [2].
The following year, the Canadian government allocated
$300 million to the provinces and territories on a per-
capita basis to launch a national HPV immunization
initiative for young girls [3]. Accordingly, the Ontario
government received $117 million and, by September
2007, implemented a program offering free HPV vacci-
nation to all Grade 8 girls in the province. The program
is administered by each of Ontario’s 36 local public
health agencies (LPHAs) primarily through school-based
immunization clinics and provides all three indicated
doses of the quadrivalent HPV vaccine. Since HPV
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any medium, provided the original work is properly cited.vaccination is not mandatory, the decision of whether or
not to receive the vaccine is left to the parents/guar-
dians of eligible girls [4].
While the initial goal of the Ontario government was
to immunize 80% of eligible girls during the program’s
first two years [5], only 53% received the first dose in
year 1 [3]. This level of vaccine coverage is not only
considerably lower than that of similar school-based
vaccination programs in the province [6], but also repre-
sents the lowest known level of HPV vaccine acceptance
in Canada [7]. The reasons for such low coverage in
Ontario remain unknown; however, surveys have consis-
tently reported that parental concerns about the safety
and long-terms effects of the HPV vaccine affect intent
to vaccinate [8-12]. As a result, clinical factors, such as
medical history and health services utilization, may be
important predictors of HPV vaccine receipt. For
instance, parents of a girl with a serious health condi-
t i o nm a yb em o r er e l u c t a n tt oc o n s e n tt oh a v i n gt h e i r
daughter receive a new vaccine for fear that it might
further impact their child’s health. On the other hand,
increased contact with healthcare providers (e.g., physi-
cians) may lead to increased opportunities to discuss the
benefits of vaccination, thereby increasing HPV vaccine
acceptance and use.
Given that low vaccine coverage undermines public
health efforts aimed at reducing the burden of HPV-
related illnesses and threatens the program’sc o s t - e f f e c -
tiveness [13,14], it is important to monitor use of the
HPV vaccine and identify factors that influence use in
order to inform future HPV immunization programs.
To this end, we conducted a population-based, retro-
spective cohort study of girls residing in Kingston, Fron-
tenac, Lennox, and Addington (KFL&A) who were
eligible for Ontario’s Grade 8 HPV vaccination program
in 2007-08 and 2008-09 to describe HPV vaccine use
and to identify socio-demographic and clinical factors
associated with this use.
Methods
This study was approved by the Research Ethics Boards
of Queen’s University and Sunnybrook Health Sciences
Centre.
The KFL&A Grade 8 HPV vaccination program
KFL&A Public Health offers the three indicated doses of
the quadrivalent HPV vaccine free-of-charge to all
Grade 8 girls in its jurisdiction. These doses are typically
administered by public health nurses in school-based
immunization clinics held in September/October,
November/December, and March/April of each year to
correspond with the recommended 0-, 2-, and 6-month
dosing schedule of the vaccine. Eligible girls also have
the option of obtaining the vaccine for free at their
LPHA or through their family physician at their conve-
nience. Under the publicly funded program, girls have
until the end of August of their Grade 8 year to initiate
the dosing schedule and until the end of their Grade 9
year to complete it.
Data sources
The study population and factors of interest were identi-
fied using Ontario’s administrative health databases and
the KFL&A Immunization Record Information System
(IRIS). The health databases used were: (1) the Regis-
tered Persons Database (RPDB) for information on dates
of health insurance coverage and socio-demographics,
(2) the Canadian Institute for Health Information’s
(CIHI) Discharge Abstract Database (DAD) for dates of
hospitalizations and discharge diagnoses (coded using
the International Classification of Diseases, Ninth and
Tenth Revisions [ICD-9 and ICD-10]), (3) the National
Ambulatory Care Reporting System (NACRS) database
for dates of emergency department visits and corre-
sponding diagnoses (coded using ICD-9 and ICD-10),
and (4) the Ontario Health Insurance Plan (OHIP) data-
base for dates and diagnoses of all fee-for-service claims
by healthcare providers who claim under the publicly
funded system (coded using OHIP diagnostic codes)
(Additional File 1: Appendix 1). These databases are gen-
erated by the province’s universal health insurance pro-
grams and are accessible through the Institute for Clinical
Evaluative Sciences (ICES). Described elsewhere in detail
[15-20], these databases have been used extensively in
health research, including in the post-marketing evaluation
of drug and vaccine safety [21-23]. In each database, resi-
dents of Ontario are represented by a unique encrypted
identifier that enables complete record linkage at the level
of the individual across databases and time.
The KFL&A IRIS database was used for information
on vaccinations. IRIS databases, maintained by each of
Ontario’s LPHAs, were originally developed by the Min-
istry of Health and Long-Term Care (MOHLTC) to
track and record immunizations mandated under the
Immunization of School Pupils Act (1982) for all school-
aged children in the province [24,25]. In addition to
mandatory vaccines, IRIS is used to maintain records on
other childhood vaccines, especially those that are pub-
licly funded. As such, IRIS captures individual-level
information on all HPV vaccines administered through
Ontario’s publicly funded program. This information is
recorded into IRIS by the LPHA, regardless of whether
the vaccine is administered at a school clinic, an LPHA,
or a physician’s office. Since parents/guardians are
required to provide their child’s immunization records
to the LPHA when the child transfers from a school in
a different health region, IRIS records are considered
up-to-date for students who move into the area. While
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recent re-abstraction study demonstrated that the
KFL&A IRIS database captured individual girls’ HPV
vaccination status with high sensitivity (99.8%; 95% CI
99.3-99.9) and specificity (97.7%; 95% CI 96.3-98.7) [26].
On April 23, 2010, a copy of the KFL&A IRIS database
was electronically transferred to ICES by means of a
secure, monitored, high encryption portal. Record link-
age with Ontario’s administrative health databases was
successful for 95.6% of individuals in the database [27].
Study design
We conducted a population-based, retrospective cohort
study of girls eligible for Ontario’s Grade 8 HPV vaccina-
tion program in KFL&A. This region was studied because
researchers were based at the KFL&A health unit and
had authorized access to the KFL&A IRIS database from
the KFL&A Medical Officer of Health. The RPDB and
KFL&A IRIS databases were used to identify girls eligible
for the 2007-08 and 2008-09 HPV immunization pro-
gram years. Since grade at which an individual is immu-
nized is not recorded in IRIS, we defined the study
cohort based on birth year and assumed all girls were in
Grade 8 thirteen years after their birth year. Accordingly,
we identified a cohort of girls born in 1994 and 1995 who
were residing in KFL&A on September 1 of 2007 and
2008, respectively. Girls were followed from September 1
of their Grade 8 school year (cohort entry) until the ear-
liest of: date of death or April 13, 2010 (end of study).
HPV vaccination history
We ascertained data on HPV vaccinations any time up
to and including the study end date. Cohort members
who initiated the vaccine series were classified as vacci-
nated (at least one dose) and those who did not were
classified as unvaccinated (no doses). Vaccinated girls
were further classified as completers if they received all
three doses or non-completers if they did not (only one
or two doses received). For both birth cohorts, data
were available to assess series completion during cohort
members’ Grade 8 year.
Baseline characteristics
The socio-demographic factors available for study were
age, income, and place of residence. Income and place of
residence were ascertained by linking a girl’sp o s t a lc o d e
at cohort entry with a measure of neighbourhood income
and community size, respectively, obtained from the 2006
Canadian Census. Neighbourhood incomes were categor-
ized into provincial quintiles and place of residence into
urban (≥10,000 persons) or rural (< 10,000) [16].
The clinical profile of each girl consisted of her vaccina-
tion history, health services utilization, and medical
history.
Data from the KFL&A IRIS database were used to
determine vaccination history; that is, if a cohort mem-
ber had been vaccinated with the measles, mumps, and
rubella (MMR; at least two doses of the vaccine),
meningococcal C (at least one dose), or hepatitis B (at
least two doses) vaccine. We used vaccination history to
assess a parent’s tendency to accept publicly funded
immunization programs on behalf of their child (i.e., a
proxy for general vaccine acceptance). Post priori,w e
also considered uptake of all three vaccines (yes/no) as a
proxy for consistent pro-vaccine sentiments.
Health services utilization was classified in terms of
the number of hospital admissions, emergency depart-
ment (ED) visits, or outpatient physician visits occurring
any time prior to cohort entry (i.e., between birth and
cohort entry). Each type of service was considered sepa-
rately and used as an indicator of health and level of
contact with the healthcare system.
We established medical histories by identifying condi-
tions leading to a hospital admission, an ED visit, or a
physician visit any time prior to cohort entry. Medical
conditions of interest included history of an autoim-
mune disease, presence of a risk factor for autoimmune
diseases, history of an immune-mediated disease, and
selected specific illnesses (Additional File 1: Appendix
2). In addition, a composite indicator of other serious
illness was identified. The list of medical diagnoses eval-
uated was developed a priori in consultation with a clin-
ical immunologist and two Public Health physicians.
This list included conditions that could predispose a girl
to an adverse event following HPV immunization (e.g.,
immune-mediated conditions) or that, because of their
seriousness, could affect the decision to vaccinate
against HPV (e.g., epilepsy, cancer).
Statistical analysis
To describe the patterns of use of the HPV vaccine, we
calculated the percentage of vaccinated and unvacci-
nated girls (series initiation) and the percentage of com-
pleters and non-completers (series completion) in the
KFL&A cohort. Subsequently, these analyses were strati-
fied by program year. We used cross-tabulations to
determine the distribution of the various socio-demo-
graphic and clinical characteristics according to series
initiation and completion and multivariable logistic
regression to estimate the strength of these associations,
adjusted for all other baseline characteristics.
All statistical analyses were conducted using SAS 9.2
(SAS Institute Inc., Cary, NC).
Results
Based on birth year, we determined that 185,398 girls
were eligible for Ontario’s Grade 8 HPV vaccination
program in its first two years (Figure 1). Of these, 2519
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study cohort. Cohort members were between 12.7 and
13.6 years of age at cohort entry.
Overall, 56.6% (n = 1425) of eligible girls received at
least one dose of the HPV vaccine and less than half
(48.2%) received all three (Figure 2). Among vaccinated
girls, 85.3% (n = 1215) completed the three dose series,
while 11.2% (n = 160) received two doses and 3.5% (n =
50) received only the first.
Series initiation increased significantly across cam-
paign years (OR = 1.29; 95% CI 1.08-1.53), but the
increase corresponded to an absolute difference of only
4.0% (Table 1). While there was no significant change in
series completion between program years (OR = 0.88;
95% CI 0.65-1.20), the proportion of non-completers
receiving two doses was higher in the second year of the
program compared to the first (13.1% vs.9 . 4 % ;p =
0.03).
After adjustment, there were no statistically significant
differences between vaccinated and unvaccinated girls
with respect to health services utilization, medical his-
tory, or socio-demographics, except girls in the fourth
income quintile were less likely to receive the HPV vac-
cine than those in the third quintile (Table 2). Conver-
sely, compared to their unvaccinated counterparts, HPV
vaccinated girls were significantly more likely to have
received the MMR (OR = 3.21; 95% CI 2.25-4.57),
meningococcal C (OR = 2.16; 95% CI 1.64-2.84), or
hepatitis B (OR = 2.86; 95% CI 2.14-3.83) vaccine and
were even more likely to have received all three vaccines
(OR = 4.89; 95% CI 4.04-5.92).
Similar to series initiation, series completion was not
significantly associated with age, health services utiliza-
tion, or medical history (Table 3). On the other hand,
series completion was associated with certain socio-
demographic characteristics. For one, girls living in the
lowest income neighbourhoods were significantly less
likely to complete the three-dose regimen than girls liv-
ing in middle-income neighbourhoods (OR = 0.45; 95%
CI 0.28-0.72). In addition, girls residing in rural areas
w e r es i g n i f i c a n t l ym o r el i k e l yt oc o m p l e t et h e i rH P V
Figure 1 Cohort flow diagram.
Figure 2 Patterns of use of the quadrivalent HPV vaccine. * This group includes two girls who received four doses.
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1.76; 95% CI 1.14-2.74). Although previous MMR,
meningococcal C, or hepatitis B vaccination was not sig-
nificantly associated with HPV vaccine completion,
receipt of all three vaccines was (OR = 1.85; 95% CI
1.29-2.65).
Discussion
Among eligible girls residing in KFL&A, HPV vaccine
initiation was low, but completion of the three-dose
regimen was high. While initiation increased signifi-
cantly between the first and second year of the immuni-
zation program, the absolute increase was small and
vaccine coverage remained far below that required to
maximize the health benefits and cost-effectiveness of
the publicly funded program. The factor most strongly
associated with series initiation was a history of vaccine
use. Income was associated with series completion, but
not initiation.
Cost has been shown to be an important barrier to
HPV vaccine use [28,29]. Therefore, our finding that
series initiation was not influenced by income demon-
strates the benefit of providing the HPV vaccine through
a publicly funded program. At the same time, we found
that those in the lowest income quintile were the least
likely to receive all three indicated doses of the vaccine,
suggesting that inequities in access may exist despite the
availability of free immunization. This is particularly
important given that low income has also been asso-
ciated with lower rates of cervical cancer screening
[30,31] and higher rates of cervical cancer incidence and
mortality [32,33]. Since non-completers may not acquire
the full benefits of HPV immunization and girls of low
income have increased need for protection against HPV-
related infections, low series completion in this popula-
tion could have important public health implications
and requires further investigation.
Although series completion was lower among those of
low income, overall, completion was high among vacci-
nated girls in our study population. This likely reflects
the convenience of a school-based program, where a girl
who received consent need only be present to receive
her scheduled dose of the vaccine. Among non-comple-
ters, girls were three times more likely to receive two
doses of the HPV vaccine as opposed to only one, sug-
gesting that lack of completion may be due to factors
additional to the withdrawal of consent. One reason for
the observed pattern may be attributed to the fact that
if a girl is absent on the day of a school immunization
clinic she must go to her LPHA or family physician to
obtain her missed dose. Low income has been consis-
tently related to school absenteeism [34-36] and it is
possible that girls of lower income have fewer resources
to follow-up on a missed dose at a location other than
their school. This hypothesis is consistent with our find-
ings that income is associated with series completion
but not initiation.
As expected, a history of vaccine use, measured using
both mandatory (MMR) and optional (meningococcal C
and hepatitis B) vaccines, was the strongest predictor of
HPV vaccine uptake. These findings are consistent with
survey data that indicate that parental attitudes and
beliefs about vaccines in general predict their attitudes
toward the HPV vaccine [8,37]. Nevertheless, in our
study cohort, overall initiation of the HPV vaccine (56%)
was still well below that of the meningococcal C (76%)
and hepatitis B (78%) vaccines that were offered to the
same girls just one year before (i.e., in Grade 7). The
low uptake of the HPV vaccine compared to these other
optional vaccines suggests that factors additional to
“anti-vaccine attitudes” are contributing to poor accep-
tance of the HPV vaccine.
Low use of the HPV vaccine in Ontario has been par-
tially attributed to the program’s rapid implementation
Table 1 Patterns of use of the quadrivalent HPV vaccine according to program year
HPV vaccination status 2007/08
N (%)
2008/09
N (%)
Adjusted OR*
(95% CI)
P-value
Series Initiation
Vaccinated 721 (54.7) 704 (58.7) 1.29 (1.08-1.53) 0.04
†
Unvaccinated 598 (45.3) 496 (41.3)
Series Completion
Completers
†† 623 (86.4) 592 (84.1) 0.88 (0.65-1.20) 0.22
Non-Completers 98 (13.6) 112 (15.9)
Received 1 dose 30 (4.2) 20 (2.8) N/A 0.03
†
Received 2 doses 68 (9.4) 92 (13.1)
OR = Odds Ratio; CI = Confidence Interval; N/A = Not Available
* Adjusted for socio-demographics, vaccination history, health services utilization, and medical history
(See Table 2 for details).
† Statistically significant (p < 0.05)
†† Includes two girls who received four doses of the vaccine.
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Characteristic * Vaccinated
(N = 1425)
Unvaccinated
(N = 1094)
Adjusted OR
†
(95% CI)
Socio-demographics
Age (mean ± SD) 13.2 ± 0.3 13.2 ± 0.3 1.10 (0.81-1.50)
Neighbourhood income quintile
1 (lowest) 18.9 20.8 0.87 (0.65-1.15)
2 17.5 18.9 0.80 (0.60-1.06)
3 (reference) 20.8 18.1 1.00 (reference)
4 20.4 21.3 0.75 (0.57-0.99)
††
5 (highest) 21.8 19.4 0.91 (0.69-1.19)
Missing
‡ 0.6 1.5 1.34 (0.50-3.61)
Place of residence
Urban (reference) 78.4 77.5 1.00 (reference)
Rural 21.1 21.0 1.14 (0.90-1.43)
Missing
‡ 0.6 1.5 1.34 (0.50-3.61)
Vaccination History
MMR 96.1 78.9 3.21 (2.25-4.57)
††
Meningococcal C 88.5 60.2 2.16 (1.64-2.84)
††
Hepatitis B 90.7 62.2 2.86 (2.14-3.83)
††
All three vaccines
§ 83.2 51.1 4.89 (4.04-5.92)
††
Health Services Utilisation
Hospitalizations
‖
None (reference) 19.5 20.4 1.00 (reference)
1 61.9 59.7 0.82 (0.63-1.07)
2 13.1 13.6 0.71 (0.50-1.01)
≥ 3 5.5 6.3 0.64 (0.38-1.06)
Emergency Department visits
‖
None (reference) 25.9 30.2 1.00 (reference)
1 21.5 22.2 1.00 (0.78-1.28)
2-7 43.4 38.9 1.16 (0.92-1.46)
≥ 8 9.2 8.7 1.13 (0.77-1.66)
Outpatient visits
‖
0-13 (reference) 8.5 12.0 1.00 (reference)
14-45 40.8 42.3 0.91 (0.64-1.31)
46-92 39.9 37.5 1.07 (0.73-1.57)
≥ 93 10.8 8.2 1.31 (0.82-2.11)
Medical History
Previous diagnosis
Infectious and parasitic diseases 15.2 13.9 0.96 (0.70-1.32)
Intestinal infections 3.7 3.3 1.25 (0.71-2.20)
Chickenpox 1.6 1.7 0.92 (0.44-1.91)
Cancer 0.9 0.6 1.55 (0.52-4.60)
Metabolic disorders 3.0 3.0 0.90 (0.50-1.61)
Disorders of the immune system 0.1 0.1 2.18 (0.07-73.24)
Diseases of the blood 1.4 1.6 0.91 (0.42-1.98)
Mental disorders 0.5 0.7 1.24 (0.38-4.03)
Epilepsy, seizures, and convulsions 3.2 3.1 1.11 (0.67-1.86)
Gastroenteritis 5.5 4.3 1.10 (0.71-1.72)
Nephritis 3.9 3.4 1.24 (0.75-2.04)
Congenital anomalies 7.0 8.9 0.78 (0.56-1.09)
Syncope 1.2 1.3 1.05 (0.47-2.35)
Other serious illness 2.0 1.8 1.05 (0.55-2.00)
Immune-mediated events
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programs that was in place at the time of the program’s
launch because of Ontario’s 2007 provincial election
campaign [38]. However, since series initiation barely
increased in the second year of the program, our results
do not support this hypothesis. Although a number of
other factors have also been proposed to explain HPV
vaccine avoidance (e.g., fear of its negative influence on
sexual behaviour, low perceived risk of HPV infection,
lack of knowledge about HPV), surveys consistently
report parental concerns about the safety and long-term
effects of vaccines as important barriers to vaccination
[8-12,39].
We were unable to directly assess whether safety
concerns affected receipt of the HPV vaccine in our
population, but we were able to explore the relation-
ship between medical history and health services utili-
zation and vaccine usage. Although these associations
were not statistically significant, there were some inter-
esting trends. First, it appeared that non-initiation was
associated with an increasing number of hospitaliza-
tions. Since admission to a hospital is a medical rather
than personal decision, a high number of hospitaliza-
tions likely indicates the presence of a serious health
problem. Therefore, as hypothesized, our results sug-
gest that parents of sicker girls may be less likely to
consent to HPV vaccination than those of relatively
healthy girls. Furthermore, in our study, a high number
of outpatient visits was associated with an increased
likelihood of receiving the HPV vaccine, suggesting
that increased contact with healthcare providers may
be related to increased vaccine acceptance. It is impor-
tant to note that, given the general good health of the
age group studied and the corresponding low event
rates, we had limited power to assess the influence of
these clinical factors on HPV vaccine receipt. As such,
these potential associations should be re-examined in a
larger sample.
Although a couple of studies have utilized administra-
tive rather than survey data to study the correlates of
HPV vaccine use in the United States [40,41], to our
knowledge, ours is the first to link a population-based
immunization database with administrative health data
i nt h ec o n t e x to fap u b l i c l yf u n d e dp r o g r a m .T h i sp r o -
vided us with a unique opportunity to report on pat-
t e r n so fu s eo ft h eH P Vv a c c i n ea n de x a m i n et h e
clinical factors associated with its acceptance in a situa-
tion in which cost of vaccination is not an issue. While
this study also benefits from the use of validated HPV
vaccination data [26], it has a number of important lim-
itations. For one, because school grade was not available
in the databases, we used birth year to identify eligible
girls. While children are typically in Grade 8 thirteen
years after they are born, this is not the case for those
who are advanced or held back a school grade. There-
fore, we may have included some ineligible girls in our
cohort (e.g., girls born in 1995 who were held back a
grade) and excluded some eligible girls (e.g., girls born
Table 2 Baseline characteristics of girls vaccinated and unvaccinated with the quadrivalent HPV vaccine (Continued)
Allergic rhinitis 0.2 0.4 0.53 (0.10-2.87)
Asthma 5.6 6.0 0.96 (0.64-1.44)
Dermatitis 4.3 3.0 1.46 (0.89-2.40)
Autoimmune diseases
Diabetes mellitus 1.3 1.7 0.57 (0.28-1.15)
Multiple sclerosis 0.0 0.1 -
Bell’s palsy 0.2 0.5 0.38 (0.08-1.69)
Guillain-Barré Syndrome 0.0 0.0 -
Juvenile Arthritis 2.2 1.7 1.28 (0.66-2.44)
Systemic Lupus Erythematosus 0.0 0.0 -
Risk factors for autoimmune diseases
Cytomegalovirus
¶ 0.0 0.1 -
Epstein-Barr virus
¶ 0.2 0.1 4.29 (0.26-71.21)
Campylobacter 0.0 0.0 -
Influenza 15.5 13.2 1.13 (0.88-1.46)
Mycoplasma pneumoniae 0.1 0.1 2.81 (0.09-87.47)
OR = Odds Ratio; CI = Confidence Interval; SD = Standard deviation; MMR = Measles, mumps and rubella
* Ascertained anytime preceding cohort entry; expressed as percentages (%) unless otherwise indicated.
† Adjusted for all characteristics listed in table as well as vaccination program year.
†† Statistically significant (p < 0.05).
‡ Missing because postal code in RPDB was either incorrect or unavailable
§ This variable was defined post-hoc and is adjusted for all factors listed except prior use of the MMR, meningococcal C, and hepatitis B vaccines.
‖ Cut points were based on the frequency distribution of the data for each variable.
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vaccine
Characteristic * Completers
(N = 1215)
Non-Completers
(N = 210)
Adjusted OR
†
(95% CI)
Socio-demographics
Age (mean ± SD) 13.2 ± 0.3 13.2 ± 0.3 1.02 (0.60-1.75)
Neighbourhood income quintile
1 (lowest) 16.9 31.0 0.45 (0.28-0.72)
††
2 17.5 17.6 0.80 (0.48-1.33)
3 (reference) 21.5 17.1 1.00 (reference)
4 21.0 16.7 0.98 (0.59-1.62)
5 (highest) 22.7 16.2 1.15 (0.68-1.92)
Missing
‡ 0.4 1.4 0.56 (0.12-2.66)
Place of residence
Urban (reference) 77.7 82.4 1.00
Rural 21.9 16.2 1.76 (1.14-2.74)
††
Missing
‡ 0.4 1.4 0.56 (0.12-2.66)
Vaccination History
MMR 96.8 92.4 1.61 (0.81-3.19)
Meningococcal C 90.0 79.5 1.39 (0.83-2.35)
Hepatitis B 92.3 81.9 1.67 (0.95-2.92)
All three vaccines
§ 85.1 72.4 1.85 (1.29-2.65)
††
Health Services Utilisation
Hospitalizations
‖
None (reference) 18.8 23.8 1.00
1 63.1 54.8 1.23 (0.80-1.91)
2 12.9 13.8 1.08 (0.59-1.98)
≥ 3 5.2 7.6 1.04 (0.45-2.37)
Emergency Department visits
‖
None (reference) 26.3 23.3 1.00
1 21.5 21.9 0.85 (0.53-1.35)
2-7 43.3 43.8 0.88 (0.58-1.35)
≥ 8 8.9 11.0 0.73 (0.38-1.40)
Outpatient visits
‖
0-13 (reference) 7.6 13.8 1.00
14-45 41.2 38.1 1.42 (0.79-2.54)
46-92 40.7 35.7 1.55 (0.83-2.89)
≥ 93 10.5 12.4 1.43 (0.67-3.05)
Medical History
Previous diagnosis
Infectious and parasitic diseases 14.5 19.1 0.83 (0.48-1.42)
Intestinal infections 3.2 6.7 0.64 (0.28-1.45)
Chickenpox 1.5 2.4 0.80 (0.25-2.59)
Cancer 0.9 1.0 0.80 (0.16-3.98)
Metabolic disorders 3.0 3.3 1.33 (0.50-3.56)
Disorders of the immune system 0.1 0.0 -
Diseases of the blood 1.6 0.5 4.60 (0.56-37.84)
Mental disorders 0.5 0.5 0.84 (0.09-8.36)
Epilepsy, seizures, and convulsions 3.1 3.8 0.89 (0.38-2.07)
Gastroenteritis 5.3 7.1 0.70 (0.36-1.37)
Nephritis 3.5 5.7 0.62 (0.29-1.30)
Congenital anomalies 7.0 7.1 0.96 (0.52-1.78)
Syncope 1.2 1.0 1.62 (0.34-7.77)
Other serious illness 2.1 1.4 1.66 (0.45-6.14)
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errors may have caused us to underestimate the number
of girls vaccinated, given the small proportion of girls
who are advanced or held back a grade, the proportion
affected by this is expected to be small. In addition,
although data were available to assess series completion
during the Grade 8 school year, we did not have vacci-
nation data after December 31, 2009. As such, series
completion for any girl in the 1995 birth cohort who
completed her regimen after December 31, 2009 of her
Grade 9 year would have been misclassified. Another
limitation is that, since the provincial health databases
contain only information on services claimed under
OHIP, the clinical history of girls who have not resided
in Ontario throughout their lifetime or who have
received privately funded care may be incomplete. Also,
t h ea c c u r a c yo fm a n yo ft h ed i a g n o s t i cc o d e su s e dt o
identify medical history has not yet been assessed, nor
has the validity of using neighbourhood income as a
proxy for household income in this population. Another
disadvantage of these administrative health data is that
we were unable to consider factors that have previously
been identified as possible predictors of HPV vaccine
acceptance, such as race/ethnicity, perceived vulnerabil-
ity to HPV infection, and concerns about the vaccine’s
long-term effects and impact on sexual behavior
[8-11,37]. Since these factors may have introduced
residual confounding into our study, the influence of
these factors on series initiation and completion now
needs to be assessed taking clinical predictors into
account. Finally, since KFL&A is a medium-sized health
district of Ontario (N = 184,407, 1.5% of the province)
with a slightly lower than average median family income
($66,466 vs. $69,156) and a low proportion of visible
minorities (5.0% vs. 23.0%) [42], the generalizability of
our results to other regions remains unclear.
Conclusions
The current low level of HPV vaccine use in KFL&A
will likely have important implications in terms of the
health benefits and cost-effectiveness of its publicly
funded vaccination program. We identified important
factors that were associated with series initiation and
completion that should be considered in efforts to guide
future HPV vaccine programming. For example, girls in
the lowest income quintile were the least likely to com-
plete the recommended three-dose regimen, suggesting
that program delivery should be modified to improve
series completion in vulnerable populations. Further-
more, since vaccine acceptance is known to be related
to concerns about the safety and long-term effects of
vaccines, our findings of possible associations between
HPV vaccine coverage and medical history and health
services utilization require further study.
Table 3 Baseline characteristics of completers and non-completers of the 3-dose regimen of the quadrivalent HPV vac-
cine (Continued)
Immune-mediated events
Allergic rhinitis 0.3 0.0 -
Asthma 5.4 6.7 0.89 (0.46-1.75)
Dermatitis 4.4 3.3 1.72 (0.72-4.14)
Autoimmune diseases
Diabetes mellitus 1.3 1.4 0.77 (0.21-2.83)
Multiple sclerosis 0.0 0.0 -
Bell’s palsy 0.3 0.0 -
Guillain-Barré Syndrome 0.0 0.0 -
Juvenile Arthritis 1.9 3.8 0.58 (0.24-1.41)
Systemic Lupus Erythematosus 0.0 0.0 -
Risk factors for autoimmune diseases
Cytomegalovirus
¶ 0.0 0.0 -
Epstein-Barr virus
¶ 0.3 0.0 -
Campylobacter 0.0 0.0 -
Influenza 15.9 13.3 1.26 (0.80-1.97)
Mycoplasma pneumoniae 0.1 0.0 -
OR = Odds Ratio; CI = Confidence Interval; SD = Standard deviation; MMR = Measles, mumps and rubella
* Ascertained anytime preceding cohort entry; expressed as percentages (%) unless otherwise indicated.
† Adjusted for all characteristics listed in table as well as vaccination program year.
†† Statistically significant (p < 0.05).
‡ Missing because postal code in RPDB was either incorrect or unavailable.
§ This variable was defined post-hoc and is adjusted for all factors listed except prior use of the MMR, meningococcal C, and hepatitis B vaccines.
‖ Cut points were based on the frequency distribution of the data for each variable.
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